Recent

% | $
Quotes you view appear here for quick access.

Cytokinetics, Incorporated Message Board

  • stan_long@ymail.com stan_long Feb 1, 2013 2:51 PM Flag

    CYTOKINETICS’ NEW PLAN WITH AMGEN INCREASES THE DOSE OF OPTIMISM TOWARDS THE H.F. DRUG

    This new development insinuates that Amgen, which holds an exclusive, world-wide (excluding Japan) license to omecamtiv mecarbil has reasons to believe in the value of Cytokinetics heart failure drug and continues to be invested in it. If anything in past investigations had raised doubt in the safety or efficacy of omecamtiv mecarbil, Amgen would have dropped its development all together by now.

 
CYTK
7.16+0.040(+0.56%)Mar 27 4:00 PMEDT